BDSX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Biodesix Inc (BDSX) is a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has strong fundamental momentum from Q1 2026 revenue growth, raised full-year guidance, improving gross margin, supportive analyst upgrades, and heavy hedge-fund buying. While the stock is extended technically and overbought near-term, the overall setup still favors buying because the user wants a direct entry now rather than waiting for a perfect pullback. I would classify it as a buy, but not an aggressive all-in position at once.
BDSX is in a clear bullish trend. MACD histogram is positive and expanding, and the moving averages are stacked bullishly with SMA_5 > SMA_20 > SMA_200, which confirms upward trend strength. Price is trading near resistance at R1 14.856 and below R2 16.37, so it is close to a breakout zone. The main caution is RSI_6 at 82.852, which is overbought and suggests the stock has run up fast in the short term. Still, trend strength outweighs the overbought reading for a long-term buyer who wants to enter now.
["Q1 2026 revenue rose 42.3% YoY to $25.6M", "Full-year 2026 revenue guidance was raised to $108M-$114M", "Gross margin improved to 83.55%", "Canaccord raised price target to $22 from $20 and kept a Buy rating", "William Blair upgraded the stock to Outperform after Q4, citing stronger-than-expected 2026 guidance and a significantly improved balance sheet", "Hedge funds have been buying heavily, with buying amount up 1991.20% over the last quarter"]
["Insiders are selling, with selling amount up 531.80% over the last month", "Net income remains negative at -$7.793M in Q1 2026", "EPS is still negative at -$0.81", "RSI is deeply overbought at 82.852, so near-term upside may be stretched", "No recent congress trading data is available", "No AI Stock Picker or SwingMax signal is present today"]
In Q1 2026, Biodesix delivered strong top-line growth, with revenue increasing 42.30% YoY to $25.555M. Gross margin improved to 83.55%, which is a favorable sign for operating leverage. However, profitability remains weak: net income was -$7.793M and EPS was -$0.81, both still negative. The key positive is that management raised full-year revenue guidance to $108M-$114M, which supports the growth narrative for the current quarter season, Q1 2026.
Analyst sentiment has improved meaningfully. On 2026-05-05, Canaccord raised its price target to $22 from $20 and maintained a Buy rating, citing higher revenue assumptions and operating margin expansion. On 2026-02-27, William Blair upgraded Biodesix to Outperform after Q4, highlighting 2026 revenue guidance that was 3% ahead of expectations and a significantly improved balance sheet. Wall Street pros are generally constructive on the stock, with the bullish case centered on accelerating growth, better margins, and balance sheet improvement. The main con is that the company is still loss-making.
